Table 2.
MSCs-Based Clinical Application for TB.
| Type of Cells | Actual Enrollment | Curative effect | Adverse events | Phase | Country | Status | Clinical trials identifier | References |
|---|---|---|---|---|---|---|---|---|
| MSCs | Spinal TB(n=20) | unknown | – | Phase 2 | Indonesia | Recruiting | NCT04493918(USA) | https://clinicaltrials.gov |
| Autologous MSCs | MDR-TB(n=15)XDR-TB(n=12) | positive | – | – | Russia | Completed | – | (119), |
| Autologous BM-MSCs | MDR/XDR-TB(n=30) | positive | high cholesterol levels (14/30, nausea (11/30) lymphopenia or diarrhea (10/30) | phase I | Belarus | Completed | DRKS00000763 (German) | (120), |
| Autologous BM-MSCs | MDR/XDR-TB(n=36) | positive | hypercholesterolaemia and nausea | – | Belarus | Completed | – | (121) |
MSCs, mesenchymal stem cells; BM-MSCs, bone marrow mesenchymal stem cells; MDR-TB, multidrug-resistant tuberculosis; XDR-TB, extensive drug resistance tuberculosis.